Related Experiment Video

Updated: Jul 5, 2026

Knockdown of FAM83A to Verify Its Role in Cervical Cancer Cell Growth and Cisplatin Sensitivity
04:20

Knockdown of FAM83A to Verify Its Role in Cervical Cancer Cell Growth and Cisplatin Sensitivity

Published on: February 9, 2024

Nuclear Factor-kappa B as a Resistance Factor to Platinum-Based Antineoplasic Drugs

Vilma Maldonado Lagunas1, Jorge Meléndez-Zajgla

  • 1Laboratorio de Biología Molecular, Subdirección de Investigación Básica, Instituto Nacional de Cancerológica, Avenida San Fernando 22, 14080 Tlalpan, Mexico.

Metal-Based Drugs
|April 17, 2008
PubMed

Insights

Platinum drugs are vital cancer treatments, but resistance is common. Inhibiting Nuclear Factor-kappa B (NF-kappa B) can overcome this resistance by sensitizing cancer cells to chemotherapy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Therapeutics

Background:

  • Platinum-based chemotherapy agents are mainstays in cancer treatment.
  • Tumor resistance, both acquired and intrinsic, frequently limits the efficacy of platinum drugs.
  • Resistance mechanisms include the evasion of apoptosis, a programmed cell death pathway.

Purpose of the Study:

  • To investigate the role of Nuclear Factor-kappa B (NF-kappa B) in cellular resistance to platinum-based chemotherapy.
  • To evaluate the potential of NF-kappa B inhibition as a strategy to overcome platinum drug resistance in cancer.

Main Methods:

  • Utilized in vitro and in vivo cancer models.
  • Assessed the impact of NF-kappa B inhibition on cancer cell sensitivity to platinum drugs.
  • Examined the relationship between NF-kappa B activity and apoptotic pathway regulation.

Main Results:

  • Nuclear Factor-kappa B (NF-kappa B) plays a critical role in determining cellular sensitivity to platinum drugs.
  • Inhibition of NF-kappa B was shown to sensitize cancer cells to the cytotoxic effects of platinum compounds.
  • These findings were consistent across both experimental settings.

Conclusions:

  • NF-kappa B is a key regulator of the cell death threshold and influences response to platinum chemotherapy.
  • Targeting NF-kappa B represents a promising therapeutic strategy to combat intrinsic and acquired resistance to platinum-based cancer treatments.

More Related Videos

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells13:38

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells

Published on: January 18, 2017

Related Concept Videos

NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Transducer Mechanism: Nuclear Receptors01:31

Transducer Mechanism: Nuclear Receptors

Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
Co-activators and Co-repressors02:04

Co-activators and Co-repressors

Gene transcription is regulated by the synergistic action of several proteins that form a complex at a gene regulatory site. This is observed in eukaryotes, where the regulation of gene expression is a complex process. Regulatory proteins in eukaryotes can broadly be classified into two types – regulators that bind directly to specific DNA sequences and co-regulators that associate with regulatory proteins but cannot directly bind to the DNA. These co-regulators are further divided into...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The Nucleolus02:55

The Nucleolus

The nucleolus is the most prominent substructure of the nucleus. When it was first discovered, it was considered to be an isolated organelle that forms fibrils and granules. In 1931, the relationship between the nucleolus and chromosomes was first described by Heitz. He observed that the appearance and size of nucleolus varies depending on the stage of the cell cycle. He also noticed constricted regions on different chromosomes clustered together at definite cell cycle stages. These regions,...